PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
7.05
Current ratio of 7.05 while GNPX has zero ratio. Bruce Berkowitz would examine if our liquidity management provides advantages.
7.05
Quick ratio of 7.05 while GNPX has zero ratio. Bruce Berkowitz would examine if our liquidity management provides advantages.
6.76
Cash ratio of 6.76 while GNPX has zero cash ratio. Bruce Berkowitz would examine if our cash management provides competitive advantages.
-2258.10
Negative interest coverage while GNPX shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
-26.70
Negative short-term coverage while GNPX shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.